Bright Minds Biosciences (DRUG) Receivables - Accured (2025 - 2026)
Bright Minds Biosciences (DRUG) posted Receivables - Accured of $714329.9 for Q1 2026, up 279.93% on a QoQ basis from $188018.6 in Q4 2025, and up 476.1% year-over-year from $123994.7 in Q1 2025.
Bright Minds Biosciences (DRUG) Receivables - Accured (2025 - 2026) Analysis & Trends
Bright Minds Biosciences' Receivables - Accured history runs 2 years deep, the most recent figure standing at $714329.9 for Q1 2026.
- Quarterly Receivables - Accured rose 476.1% year-over-year to $714329.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $714329.9 (up 476.1% YoY) and the FY2025 annual result came in at $147618.1, changed N/A from the prior year.
- Receivables - Accured was $714329.9 for Q1 2026 at Bright Minds Biosciences, up from $188018.6 in the prior quarter.
- Across five years, Receivables - Accured topped out at $714329.9 in Q1 2026 and bottomed at $123994.7 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Bright Minds Biosciences | 498.53 Mn | 498.53 Mn | - | 714,329.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 714,329.90 |
| Mar 31, 2026 | 714,329.90 |
| Dec 31, 2025 | 188,018.59 |
| Dec 31, 2025 | 188,018.59 |
| Sep 30, 2025 | 147,618.08 |
| Sep 30, 2025 | 147,618.08 |
| Mar 31, 2025 | 123,994.68 |
| Mar 31, 2025 | 123,994.68 |